托法替尼(托法替布)怎么购买?

Purchasing channels for the Bangladeshi version of Tofacitinib (Tofacitinib)

The Bangladeshi version of Tofacitinib (Tofacitinib) has not been launched in mainland China as of January 26, 2024 The current purchasing channels for the Bangladeshi version of Tofacitinib are as follows:

1. Go to Bangladesh to purchase, see a doctor in a local hospital, and use medication under the doctor’s evaluation. However, this method requires traveling far and requires a heavy financial burden, and is not suitable for long-term medication.

2. Patients can also obtain it through the help of domestic professional overseas medical service institutions, but they need to find formal and qualified medical service institutions online. This method is more secure and can sign a contract to ensure that the drugs are genuine. In addition, this method can be mailed directly to your home without having to travel far, which is more cost-effective.

Currently, we know that the price of Tofacitinib (Tofacitinib) Bangladesh Yaopin International Edition and Bangladesh Beacon Edition is about 300$ to 600$; different dosage forms and different pharmaceutical companies will also have different drug prices. It is recommended that patients purchase from regular channels to avoid being deceived and buying counterfeit drugs, which will affect the treatment of the original drugs.

Dosage of Tofacitinib

The dosage of Tofacitinib may vary depending on the specific autoimmune disease being treated and the individual patient's medical history. Typically, Tofacitinib tablets are taken once daily.

Rheumatoid Arthritis: The usual starting dose is 5 mg PO twice daily (10 mg total daily). Some patients may be prescribed a higher dose, such as 11 mg once daily, depending on the severity of the condition and its response to treatment.

Psoriatic Arthritis: The typical starting dose is 5 mg PO twice daily (10 mg total daily). As with rheumatoid arthritis, some people may take tofacitinib 11 mg once daily.

Therapeutic efficacy of tofacitinib

A trial in which Japanese patients aged 20 years or older with moderate to severe plaque psoriasis and/or psoriatic arthritis were double-blindly randomized in a 1:1 ratio to receive 5 or 10 mg twice daily for 16 weeks, 10 Open-label treatment at a mg twice daily dose for 4 weeks, then variant 5 or 10 mg twice daily doses through week 52.

The primary endpoints at Week 16 were the proportion of patients with psoriasis who achieved at least a 75% reduction in the Psoriasis Area and Severity Index (PASI75) and a physician's global assessment of "clear" or "substantially clear" of psoriasis (PGA response); and a 20% or greater improvement in the American College of Rheumatology criteria (ACR20) in patients with psoriatic arthritis.

Test results

Safety assessment is carried out throughout. 87 patients met eligibility criteria for moderate to severe plaque psoriasis, with 62.8% and 72.7% achieving PASI75 at week 16 on basal doses of tofacitinib (tofacitinib) 5 mg and 10 mg, respectively; 67.4% and 68.2% of patients achieved a PGA response; and all patients with psoriatic arthritis achieved ACR20. Responses persisted through week 52.

Tofacitinib (two doses) has been effective for 52 weeks in patients with moderate to severe plaque psoriasis and/or psoriatic arthritis; safety results are generally consistent with previous studies. For more information on adverse reactions and effects, please click: read this article.

Tofacitinib is a drug that affects the immune system and reduces its ability to fight infection. Some people may develop serious infections while taking tofacitinib, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. It is recommended that patients take medication under the guidance of a doctor and receive symptomatic treatment.

Note: The above information comes from the U.S. FDA drug instructions and network integration. Please follow your doctor's advice when taking medication and do not use it blindly.

Recommended hot articles:

References

Asahina A, Etoh T, Igarashi A, Imafuku S, Saeki H, Shibasaki Y, Tomochika Y, Toyoizumi S, Nagaoka M, Ohtsuki M; study investigators. Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study. J Dermatol. 2016 Aug;43(8):869-80. doi: 10.1111/1346-8138.13258. Epub 2016 Feb 15. PMID: 26875540; PMCID: PMC5067558.